Skip to main content
. 2023 Feb 15;2023:1225676. doi: 10.1155/2023/1225676

Table 2.

IAS-related drugs and the number of cases (N).

Related drugs N
Methimazole 170 (21.38%)
Alpha lipoic acid 51 (6.42%)
Clopidogrel 8 (1.01%)
Esomeprazole 1 (0.13%)
Captopril 8 (1.01%)
Insulin and its analogues 20 (2.52%)
Sulfhydryl-containing health products 2 (0.25%)
Insulin aspartate 30 27 (3.40%)
Insulin glargine 2 (0.25%)
Glucosamine sulfate-containing drugs 1 (0.13%)
Insulin lispro 3 (0.38%)
131I therapy 2 (0.25%)
Mercaptan 2 (0.25%)
Tiopronin 54 (6.80%)
Zinc protamine recombinant human insulin 11 (1.38%)
Acetylcysteine 1 (0.13%)
Penicillamine 2 (0.25%)
Carbimazole 3 (0.38%)
Propylthiouracil 3 (0.38%)
Penicillin G 1 (0.13%)
Ganshulin 50R 2 (0.25%)
Coenzyme Q10 1 (0.13%)
Omeprazole 1 (0.13%)
Human serum albumin 1 (0.13%)
Antituberculosis treatment 2 (0.25%)
Loxoprofen sodium 2 (0.25%)
Insulin glulisine 1 (0.13%)
Pantoprazole 1 (0.13%)
Methionine-containing supplements 1 (0.13%)
Imipenem 1 (0.13%)
Azathioprine 1 (0.13%)
Glimepiride 1 (0.13%)
Glutathione 8 (1.01%)
Gold thioglucoce 1 (0.13%)
Acegratone 1 (0.13%)
Interferon-alfa 1 (0.13%)
Gliclazide 1 (0.13%)
Unknown or no 399 (50.19%)
Total 795